1-Year Patency of Biorestorative Polymeric Coronary Artery Bypass Grafts in an Ovine Model.

Autor:	Ono M; Amsterdam Universitair Medische Centra, University of Amsterdam, Heart Center, Department of Clinical and Experimental Cardiology, Amsterdam Cardiovascular Sciences, Amsterdam, the Netherlands.; Department of Cardiology, National University of Ireland, Galway (NUIG), Galway, Ireland., Kageyama S; Department of Cardiology, National University of Ireland, Galway (NUIG), Galway, Ireland., O'Leary N; Department of Cardiology, National University of Ireland, Galway (NUIG), Galway, Ireland., El-Kurdi MS; Xeltis BV, Eindhoven, the Netherlands., Reinöhl J; Xeltis BV, Eindhoven, the Netherlands., Solien E; American Preclinical Services, LLC, Minneapolis, Minnesota, USA., Bianco RW; Experimental Surgical Services, University of Minnesota, Minneapolis, Minnesota, USA., Doss M; Department of Cardiac Surgery, Helios Clinic, Siegburg, Germany., Meuris B; Department of Cardiac Surgery, University Hospital Leuven, Leuven, Belgium., Virmani R; CVPath Institute, Inc, Gaithersburg, Maryland, USA., Cox M; Xeltis BV, Eindhoven, the Netherlands., Onuma Y; Department of Cardiology, National University of Ireland, Galway (NUIG), Galway, Ireland., Serruys PW; Department of Cardiology, National University of Ireland, Galway (NUIG), Galway, Ireland.; NHLI, Imperial College London, London, United Kingdom.
Jazyk:	angličtina
Zdroj:	JACC. Basic to translational science [JACC Basic Transl Sci] 2022 Nov 09; Vol. 8 (1), pp. 19-34. Date of Electronic Publication: 2022 Nov 09 (Print Publication: 2023).
DOI:	10.1016/j.jacbts.2022.06.021
Abstrakt:	Many attempts have been made to inhibit or counteract saphenous vein graft (SVG) failure modes; however, only external support for SVGs has gained momentum in clinical utility. This study revealed the feasibility of implantation, and showed good patency out to 12 months of the novel biorestorative graft, in a challenging ovine coronary artery bypass graft model. This finding could trigger the first-in-man trial of using the novel material instead of SVG. We believe that, eventually, this novel biorestorative bypass graft can be one of the options for coronary artery bypass graft patients who have difficulty harvesting SVG. Competing Interests: The work described in this paper was fully funded by Xeltis BV. Drs El-Kurdi, Reinöhl, and Cox are all employees of Xeltis. Dr Virmani has received personal fees from Xeltis, and Medtronic; as well as Institutional grants from Abbott Vascular, Boston Scientific, Medtronic, Xeltis and Becton Dickinson. Prof. Onuma has received institutional research grants related to his work as the Chairman of cardiovascular imaging core labs of several clinical trials and registries sponsored by industry, for which he receives no direct compensation. Prof. Serruys has received personal fees from Sino Medical Sciences Technology, Philips/Volcano and Xeltis. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose. (© 2023 The Authors.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu